Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Bone density Stories

2011-01-15 00:00:44

FRAX, a new tool for estimating a person's risk of fractures and bone breaks is in use by physicians at Summit Medical Group (SMG). Berkeley Heights, NJ (Vocus/PRWEB) January 13, 2011 FRAX, a new tool for estimating a person's risk of fractures and bone breaks is in use by physicians at Summit Medical Group (SMG). "As adults age, we lose bone mass, which can make bones fragile and prone to fracture and breaks," notes Robert L. Rosenbaum, M.D., SMG endocrinologist. One of the more serious...

2010-12-27 13:41:42

IOF and IFCC experts recommend international reference standards for use of bone turnover markers in clinical studies An expert working group of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has released a new position paper which reviews the evidence of bone turnover markers (BTMs) in fracture risk prediction and monitoring of osteoporosis therapy. More importantly, it identifies research priorities and...

2010-11-18 17:11:06

Taking time off from certain osteoporosis drugs may be beneficial to bone health, according to a study conducted at Loyola University Health System. Researchers found that bone density remained stable for three years in patients who took a drug holiday from bisphosphonates, a popular class of osteoporosis drugs that can cause fractures in the thigh bones and tissue decay in the jaw bone. "These drugs are potentially harmful when taken for long durations, yet little has been known until now...

2010-11-16 19:40:14

Three days of critical international discussion and debate, led by a panel of experts from the ISCD and IOF, have served to clarify a number of important questions pertaining to the interpretation and use of FRAX® in clinical practice. Three days of critical international discussion and debate, led by a panel of experts from the International Society of Clinical Densitometry (ISCD) and the International Osteoporosis Foundation (IOF), have served to clarify a number of...

2010-11-16 11:17:00

NEW YORK, Nov. 16, 2010 /PRNewswire/ -- See video from International Osteoporosis Foundation at: http://www.thenewsmarket.com/CustomLink/CustomLinks.aspx?GUID=72690337-6fc0-4bf1-8833-45ae38f30e57&alertid=b6f7ca94-a2d2-4716-93fd-60c34a56470e The International Osteoporosis Foundation (IOF) and the International Society of Clinical Densitometry (ISCD) convened to clarify a number of important questions regarding the use of FRAX® in clinical practice. The WHO Fracture...

2010-11-05 07:00:00

THOUSAND OAKS, Calif., Nov. 5, 2010 /PRNewswire/ -- Amgen (Nasdaq: AMGN) is pleased to announce that it has won the Best New Drug award for Prolia(TM) (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the 2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME's Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that break...

2010-10-19 08:47:35

(Ivanhoe Newswire) --  A new study shows that women with high T-scores don't need screening every two years, but at least every ten years. "If a woman's bone density at age 67 is very good, then she doesn't need to be re-screened in two years or three years, because we're not likely to see much change," Margaret L. Gourlay, MD, MPH of the University of North Carolina at Chapel Hill School of Medicine and author of this study was quoted as saying. "Our study found it would take about 16...

2010-10-18 12:57:15

Since 2002, the U.S. Preventive Services Task Force has recommended that women ages 65 and older be routinely screened for osteoporosis and has suggested that a 2-year screening interval might be appropriate. However, what length the screening interval should be is a topic that remains controversial and undecided, with no definitive scientific evidence to provide guidance. Now a new study led by Margaret L. Gourlay, MD, MPH of the University of North Carolina at Chapel Hill School of Medicine...

2010-10-16 15:45:00

EAST HANOVER, N.J., Oct. 16 /PRNewswire/ -- Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in postmenopausal women with osteoporosis.(1) The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada. The study showed that Reclast maintained bone mass in...

2010-10-14 16:01:00

THOUSAND OAKS, Calif., Oct. 14 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that results from several Prolia(TM) (denosumab) studies, as well as analyses of the growing global burden of osteoporosis, will be presented at the 2010 American Society for Bone and Mineral Research (ASBMR) annual meeting in Toronto, Ontario from Oct. 15-19, 2010. "The continued need to reduce fractures caused by postmenopausal osteoporosis is reinforced by data that will be presented at this year's...